Our Pipeline

F I B R O S I S

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Idiopathic Pulmonary Fibrosis (IPF)

​

Radiation Induced Pulmonary Fibrosis (RIPF)

​

Chronic Kidney Disease (CKD)

​

Non-alcoholic steatohepatitis (NASH)

​

Androgenic Alopecia (AGA)

​

​

Alzheimer's Disease (AD)

​

​

Type 2 Diabetes (T2D)

​

​

COVID-19

D E R M A T O L O G Y

C N S

M E T A B O L I C

V I R A L

Partnership

If you are interested in partnering with us for the clinical development and the commercialization of novel RNAi therapeutics using our proprietary SAMiRNA™ technology, please contact us at
collaborations@sirnagen.com or fill out a form below.